Pharma: Other News To Note
Wednesday, August 1, 2012
Intellipharmaceutics International Inc., of Toronto, said it reached an agreement with London-based AstraZeneca plc to settle all outstanding patent litigation concerning its abbreviated new drug application to commercialize a generic version of AstraZeneca's Seroquel XR (quetiapine fumarate extended-release) tablets.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.